Switching from reference infliximab to biosimilar CT-P13 did not change quality of life in stable inflammatory bowel disease patients

Pierik, M.J.; Meulen, A.E. van der; Linde, K. van der; Lutgens, M.; Kuijvenhoven, J.P.; Akol, H.; ... ; Dijkstra, G. (2022)

Article / Letter to editor

Background

Quality of life (QoL) data for patients with inflammatory bowel disease switched from the reference infliximab to biosimilar CT-P13 is lacking. This study aims to demonstrate noninferiority for QoL and efficacy after switching.

Methods

OoL and clinical efficacy were measured prior to and after 2, 4, and 6 CT-P13 infusions.

Results

One hundred seventy-eight patients were included. Noninferiority was established for QoL [ratio 97.95% (95% confidence interval 95.93 to 100.01)] and efficacy [difference −0.02 (95% confidence interval −0.68 to 0.64)]. Five patients reported 6 nonrelated, serious adverse events.

Conclusions

Switching from reference infliximab to CT-P13 did not affect the QoL or disease activity and was well tolerated.

• quality of life
• infliximab
• biosimilar
• inflammatory bowel disease

• All authors: Pierik, M.J.; Meulen, A.E. van der; Linde, K. van der; Lutgens, M.; Kuijvenhoven, J.P.; Akol, H.; Klompmaker, I.J.; Sikkens, M.S.G.; Megen, Y.J.B. van; Stoop, C.M.; Bloemsaat-Minekus, J.P.J.; Dijkstra, G.
• Date: 2022-07-01
• Journal: Crohn's & Colitis 360
• Volume: 4
• Issue: 3
• DOI: doi:10.1093/crocol/otab001
• Link: https://academic.oup.com/crohnscolitis360/article/4/3/otab001/6134810